Clinical Trial Update: A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD [Phase 1]

View source ↗

Summary

Phase 1 safety evaluation of single and repeated intravitreal doses of JSM6427 for age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• JSM6427

Snippet

Sponsor: Jerini Ophthalmic | Conditions: Macular Degeneration | Phase 1 | Status: COMPLETED